- Year-to-date revenue declined by 2.8% at CER and 3.3% at AER.
- Core operating profit fell by 3.4% at both CER and AER.
- Takeda submitted NDAs for oveporexton and rusfertide, with zasocitinib filing planned.
- New drug launches expected within 18 months.
Financial Performance
Takeda reported a year-to-date revenue decline of 2.8% at constant exchange rates (CER) and 3.3% at actual exchange rates (AER), with core operating profit decreasing by 3.4% at both CER and AER. However, reported operating profit increased by 1.2% at AER, driven by lower restructuring expenses offsetting impairment costs.
Impact of VYVANSE® Generics
The impact of VYVANSE® generics is tapering off, narrowing the gap between growth in new product revenue and VYVANSE erosion. Operational efficiencies have led to reductions in operating expenses, including R&D costs.
Future Growth and Drug Launches
Takeda is positioned for long-term growth with multiple late-stage programs having multibillion-dollar peak revenue potential. Following positive Phase 3 study results in 2025, the company has submitted New Drug Applications (NDAs) for oveporexton and rusfertide, with plans to file an NDA for zasocitinib. These programs are expected to launch within the next 18 months.
